A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard Carfilzomib, and High-dose Weekly Carfilzomib and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Latest Information Update: 09 May 2025
At a glance
- Drugs Carfilzomib (Primary) ; Isatuximab (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 May 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 01 May 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 06 Dec 2024 According to a Kymera Therapeutics media release, the John Theurer Cancer Center Researchers to present data from this trial at the 66th Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, California, from December 7-10, 2024.